NCCN Foundation Announces 2012 Young Investigator Awards
The NCCN Foundation has awarded the second series of Young Investigator Awards to four young investigators from NCCN Member Institutions. The 2012 awards focus on assessing and improving outcomes of cancer care and provide grants of $150,000 over a two-year period.
FORT WASHINGTON, PA— The NCCN Foundation, which through private philanthropy and grants, advances the mission of the National Comprehensive Cancer Network® (NCCN®) to improve the quality and effectiveness of care for patients with cancer, has awarded grants to four young investigators from NCCN Member Institutions dedicated to advancing and discovering new treatments for cancer. These awards represent the second series of the NCCN Foundation Young Investigator Awards, a program initiated in 2011. Each of the funded research initiatives will focus on assessing or improving outcomes of cancer care and provide grants of $150,000 over a two-year period. Funding will begin September 1, 2012.
The goal of the NCCN Foundation Young Investigator Awards is to cultivate the next generation of cancer researchers at NCCN Member Institutions. We are very proud that we are able to continue to support young investigators at a time when defining quality in cancer care and supporting science is so essential, said Cindy McGirk, RN, MBA, JD, Executive Director, Foundation & Legal Affairs, at NCCN.
Congratulations to the 2012 awardees:
Piero Dalerba, MD, Instructor of Medicine, Stanford Cancer Institute. Dr. Dalerba`s research initiative is titled Evaluation of CDX2 as a novel predictive biomarker to guide therapeutic algorithm design in colon cancer.
Crystal Denlinger, MD, Assistant Professor, Fox Chase Cancer Center. Dr. Denlinger`s research initiative is titled Adherence to NCCN survivorship care guidelines in non-small cell lung cancer and colorectal cancer survivor care.
Ronan Kelly, MD, MBA, Assistant Professor, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Kelly`s research initiative is titled Assessing the impact on chemotherapy decision making while utilizing the NCCN Guidelines when the cost of each regimen is provided to prescribers and patients.
Elissa Ozanne, PhD, Assistant Professor, UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Ozanne`s research initiative is titled Impact of implementing the NCCN Guidelines for genetic/familial high-risk assessment: breast and ovarian in clinical practice.
The awardees responded to a Request for Proposal (RFP) issued by the NCCN Foundation to the 21 NCCN Member Institutions. All submissions were reviewed by a multidisciplinary panel of oncology experts, and the awardees were selected based on several key components, including scientific merit and study design.
The Young Investigator Awards represent a significant initiative for NCCN and the NCCN Foundation to support promising young researchers in oncology. It was exciting to again see so many excellent proposals, addressing many different cancer types and issues, said F. Marc Stewart, MD, Medical Director, Seattle Cancer Care Alliance, a member of the review committee.
These awards were made possible via contributions from the following companies: Abbott Labs, Celgene, Genentech, Millennium Pharmaceuticals, Pfizer, and Teva.
About the NCCN Foundation
The NCCN Foundation was initiated in 2010, with a key goal in the first year of raising funds for the development and distribution of the NCCN Guidelines for Patients™. Nine of these guidelines for patients are now available with another three planned for 2012. The NCCN Guidelines for Patients™ use the same treatment algorithms that are the hallmark of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), but are translated into a more user-friendly format utilizing language for non-professional audiences. The Young Investigator Awards represent another major programmatic initiative for the NCCN Foundation.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center
Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Memorial Sloan-Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center